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OBJECTIVES We sought to determine the relative impact of diabetes mellitus on prognosis in ischemic
compared with nonischemic cardiomyopathy.
BACKGROUND Ischemic myocardium is characterized by increased reliance on aerobic and anaerobic
glycolysis. Because glucose utilization by cardiomyocytes is an insulin-mediated process, we
hypothesized that diabetes would have a more adverse impact on mortality and progression
of heart failure in ischemic compared with nonischemic cardiomyopathy.
METHODS We performed a retrospective analysis of the Studies Of Left Ventricular Dysfunction
(SOLVD) Prevention and Treatment trials.
RESULTS In adjusted analyses, diabetes mellitus was strongly associated with an increased risk for
all-cause mortality in patients with ischemic cardiomyopathy, (relative risk [RR] 1.37, 95%
confidence interval [CI] 1.21 to 1.55; p , 0.0001), but not in those with nonischemic
cardiomyopathy (RR 0.98, 95% CI 0.76 to 1.32; p 5 0.98). The increased mortality in
patients with ischemic cardiomyopathy compared with nonischemic cardiomyopathy was
limited to those with ischemic cardiomyopathy and diabetes mellitus (RR 1.37, 95% CI 1.21
to 1.56; p , 0.0001). When patients with ischemic cardiomyopathy and diabetes mellitus
were excluded, there was no significant difference in mortality risk between the ischemic and
nonischemic cardiomyopathy groups after adjusted analysis (RR 0.99, 95% CI 0.86 to 1.15;
p 5 0.99). Previous surgical revascularization identified patients within the cohort with
ischemic cardiomyopathy and diabetes mellitus, with improved prognosis.
CONCLUSIONS The differential impact of diabetes on mortality and heart failure progression according to the
etiology of heart failure suggests that diabetes and ischemic heart disease interact to accelerate
the progression of myocardial dysfunction. Evaluation of the potential for revascularization
may be particularly important in patients with ischemic cardiomyopathy and diabetes
mellitus. (J Am Coll Cardiol 2001;38:421–8) © 2001 by the American College of
Cardiology
A report from the original Studies Of Left Ventricular
Dysfunction (SOLVD) investigators clearly identified dia-
betes mellitus as an independent predictor of increased
mortality in heart failure (1). However, the relative prog-
nostic impact of diabetes mellitus in ischemic compared
with nonischemic cardiomyopathy has not been well char-
acterized. Ischemic myocardium is characterized by in-
creased reliance on glucose for both aerobic and anaerobic
glycolysis, as well as decreased utilization of free fatty acids
for energy metabolism (2,3). The utilization of glucose by
cardiomyocytes is an insulin-mediated process (4). We
hypothesized, therefore, that diabetes mellitus would have a
more deleterious impact on mortality and heart failure
progression in ischemic compared with nonischemic cardio-
myopathy. In addition, the prevailing opinion is that isch-
emic cardiomyopathy is associated with a more adverse
prognosis than nonischemic cardiomyopathy (5). We were
interested in determining the implications of the relative
prognostic impact of diabetes mellitus according to the
etiology of heart failure, based on our understanding of the
epidemiology of ischemic and nonischemic cardiomyopa-
thy. To address these hypotheses, we conducted a retrospec-
tive analysis of the 6,797 participants in the SOLVD
Prevention and Treatment trials.
METHODS
Patient population. The SOLVD Prevention and Treat-
ment trials studied the survival benefit of enalapril in
patients with asymptomatic and symptomatic heart failure,
respectively. There were 4,228 participants in the Preven-
tion trial, which enrolled patients with asymptomatic left
ventricular systolic dysfunction. The SOLVD Treatment
trial enrolled 2,569 patients with symptomatic systolic heart
failure. The details of the rationale and design of the
SOLVD trials have been published (6).
Patients were eligible for either trial if they had a
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documented ejection fraction #35%. Participants were ran-
domized to the angiotensin-converting enzyme inhibitor,
enalapril, or placebo. Exclusion criteria included active
angina pectoris requiring surgical intervention, unstable
angina, myocardial infarction within one month, renal
failure (defined as a creatinine value .2.0 mg/dl) or severe
pulmonary disease.
Defining etiology of left ventricular systolic dysfunction.
In each enrolled participant, the SOLVD site investigator
determined the most likely etiology of heart failure and
indicated it on the baseline form. Choices included “isch-
emic,” “nonischemic” and “other.” This was based on the
site investigator’s opinion after reviewing all of the available
information. The subjects did not routinely undergo cardiac
catheterization or noninvasive testing to make this determi-
nation. For the present analysis, we refined the definition of
ischemic etiology to minimize misclassification. The present
analysis defined a participant as having an ischemic etiology
of heart failure if any of the following were present: 1)
classification as ischemic etiology by original SOLVD
investigator; 2) previous myocardial infarction; and 3) pre-
vious surgical revascularization.
Definition of diabetes. The baseline form, completed for
all participants, included information on the presence or
absence of a history of diabetes mellitus. Data on the
duration of diabetes, severity of diabetes (i.e., glycosylated
hemoglobin) and medications used to treat diabetes were
not available. For the purposes of the present analysis, we
studied the impact of diabetes mellitus by stratifying pa-
tients into those with and without a history of diabetes
mellitus at baseline.
Definitions of end points. The cause of death was deter-
mined by the site investigators after a detailed review of the
circumstances of death. Categories included “pump failure,”
“arrhythmia with antecedent worsening of heart failure” and
“arrhythymia with no antecedent worsening of heart fail-
ure.” For the present analysis, we defined pump failure death
to include those deaths, attributed by the original SOLVD
investigators, as due to “pump failure,” as well as those
attributed to “arrhythmia with antecedent worsening of
heart failure.” Consequently, the definition of “arrhythmic
death” in the present analysis was limited to those deaths
classified by the original SOLVD investigators as “arrhyth-
mia with no antecedent worsening of heart failure.” The
definition of death due to myocardial infarction was not
standardized, but was based on a detailed review of all
information available on each death by the original SOLVD
investigators.
Data collection, definitions and statistical analysis.
Baseline data were collected at the time of enrollment in
either of the SOLVD trials. Group comparisons of contin-
uous data were done using the Student t test, assuming
unequal variances in the comparison groups when appropri-
ate. Group comparisons of categorical data were done using
the chi-square test. A p value #0.05 was considered
statistically significant. Kaplan-Meier survival curves were
formally compared by using the log-rank test.
Univariate and multivariate relationships were investi-
gated using a Cox proportional hazards model. Two-sided
95% confidence intervals were constructed around each
point estimate of relative risk, and a p value #0.05 was
considered statistically significant. For multivariate analyses,
participants in the Prevention and Treatment trials were
combined to increase statistical power. In the adjusted
analyses, age and left ventricular ejection fraction were
analyzed as continuous variables. The following variables
were analyzed as dichotomous variables: gender, SOLVD
trial (Treatment vs. Prevention), self-reported race/ethnicity
(African-American/black vs. white or other), baseline use of
beta-blocker (yes vs. no), aspirin (yes vs. no), New York
Heart Association (NYHA) functional class (III or IV vs. I
or II) and randomization assignment (enalapril vs. placebo).
Statistical analyses were conducted using the Statistical
Analysis Software (SAS), version 8.0 (Cary, North Carolina).
RESULTS
Baseline comparisons (Tables 1 and 2). Of the partici-
pants with an ischemic etiology of heart failure, those with
diabetes mellitus in each trial were older and more of them
were African-American, compared with those without a
history of diabetes mellitus. In the Treatment trial, the
patients with ischemic cardiomyopathy and diabetes melli-
tus had more advanced heart failure according to NYHA
functional class, but a slightly higher mean ejection fraction.
Of the participants with a nonischemic etiology of heart
failure, those with diabetes in each trial were slightly older
than the nondiabetic subjects. In the Prevention trial, the
nonischemic diabetic cohort had a greater proportion of
women. In the Treatment trial, the nonischemic diabetic
cohort had slightly increased baseline creatinine levels and a
greater proportion with NYHA functional class III or IV
heart failure symptoms, compared with the nonischemic
subjects without diabetes. The overall prevalence of surgical
revascularization was similar in patients with and without
diabetes mellitus among those with ischemic cardiomyopa-
thy in the Prevention trial, but in the Treatment trial, the
patients with diabetes mellitus had a slightly lower preva-
lence of previous surgical revascularization.
Prognostic impact of diabetes is influenced by etiology of
heart failure. Marked differences in the association be-
tween diabetes and mortality were demonstrated in partic-
Abbreviations and Acronyms
NYHA 5 New York Heart Association
SOLVD 5 Studies Of Left Ventricular Dysfunction
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ipants stratified by etiology of heart failure. As demon-
strated in multivariate analysis (Table 3), diabetes remained
independently associated with an increased risk of all-cause
mortality, pump failure death and the composite end point
(death from any cause or hospital admission for heart
failure) in the subjects with ischemic cardiomyopathy;
however, there was no association between diabetes and
outcomes in the nonischemic cohort. The p value for
evidence of interaction between diabetes mellitus and the
etiology of heart failure upon the risk for all-cause mortality
was highly significant (p 5 0.007).
Because diabetes mellitus was not associated with prog-
nosis in nonischemic cardiomyopathy, we combined the
diabetic and nondiabetic subjects with nonischemic cardio-
myopathy into a single cohort. Survival was compared in
each trial by separating the subjects into three cohorts: 1)
patients with ischemic cardiomyopathy and no history of
diabetes mellitus; 2) patients with nonischemic cardiomy-
opathy with or without a history of diabetes mellitus; and 3)
patients with ischemic cardiomyopathy and a history of
diabetes mellitus. The unadjusted survival curves for these
three cohorts in each of the SOLVD trials are demonstrated
in Figures 1 and 2. In each trial, the cohort with ischemic
cardiomyopathy and diabetes mellitus experienced the
greatest mortality. In the Prevention trial, the nonischemic
cohort’s mortality was higher than that of the patients with
ischemic cardiomyopathy without diabetes mellitus. In the
Treatment trial, the survival of the patients with ischemic
Table 1. Baseline Characteristics of Patients Stratified by Etiology of Heart Failure and Diabetes
Status: SOLVD Prevention Trial









Age (years) 61.6 6 8.9 59.1 6 10.1* 60.4 6 9.5 56.5 6 12.8†
Ejection fraction (%) 28.7 6 5.4 28.6 6 5.5 28.3 6 5.7 26.9 6 6.3
Creatinine (mg/dl) 1.15 6 0.29 1.15 6 0.26 1.16 6 0.40 1.14 6 0.38
CABG 35.0% 34.4% 0% 0%
History of MI 88.4% 93.1%* 0% 0%
History of hypertension 51.3% 33.8%* 63.9% 37.6%*
Atrial fibrillation 2.9% 2.3% 12.5% 14.5%
Gender
Male 86.8% 90.3%‡ 73.6% 83.5%‡
Female 13.2% 9.7%‡ 26.4% 16.5%‡
Race
Black 13.7% 5.9%* 31.9% 24.3%
White 86.3% 94.1%* 68.1% 75.7%
Randomization to enalapril 51.3% 50.1% 43.1% 47.8%
*p # 0.001; †p # 0.01 and .0.001; ‡p # 0.05 and .0.01 for comparisons between diabetics and nondiabetics in each etiology
group. Data are presented as the mean value 6 SD or percentage of patients.
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction; SOLVD 5 Studies Of Left Ventricular
Dysfunction.
Table 2. Baseline Characteristics of Patients Stratified by Etiology of Heart Failure and Diabetes
Status: SOLVD Treatment Trial









Age (years) 63.2 6 8.0 61.5 6 9.3* 60.1 6 9.8 57.2 6 12.0†
Ejection fraction (%) 26.0 6 6.5 25.0 6 6.6† 24.6 6 6.9 23.3 6 6.9
Creatinine (mg/dl) 1.25 6 0.35 1.24 6 0.30 1.30 6 0.33 1.21 6 0.31†
CABG 27.5% 33.2%‡ 0% 0%
History of MI 86.5% 88.0% 0% 0%
History of hypertension 52.1% 37.2%* 60.5% 41.1%*
Atrial fibrillation 6.4% 5.9% 12.4% 23.2%†
Gender
Male 78.3% 84.4%† 68.2% 74.7%
Female 21.7% 15.6%† 31.8% 25.3%
Race
Black 16.7% 8.8%* 28.7% 28.9%
White 83.3% 91.2%* 71.3% 71.1%
Randomization to enalapril 48.3% 49.4% 48.1% 54.2%
*p # 0.001; †p # 0.01 and .0.001; ‡p # 0.05 and .0.01 for comparisons between diabetics and nondiabetics in each etiology
group. Data are presented as the mean value 6 SD or percentage of patients.
Abbreviations as in Table 1.
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cardiomyopathy without diabetes mellitus was indistin-
guishable from that of the patients with nonischemic
cardiomyopathy.
Results of adjusted analyses (Table 4). After adjusting for
potential confounders, the cohort consisting of patients with
ischemic cardiomyopathy and diabetes mellitus demon-
strated an increased risk of all-cause mortality, compared
with the cohort with ischemic cardiomyopathy without
diabetes mellitus and the cohort of nonischemic cardiomy-
opathy. The increased risk in the ischemic diabetic cohort,
compared with the ischemic nondiabetic cohort, was related
to an increased risk of pump failure death and a trend
toward an increased risk of arrhythmic deaths, but no
significant increase in the risk of death attributed to fatal
myocardial infarction. The increased risk of all-cause mor-
tality in the ischemic diabetic cohort, compared with the
nonischemic cohort, was related to an increased risk for each
mode of cardiovascular death. There was no significant
difference in mortality risk when comparing the cohort with
ischemic cardiomyopathy without diabetes mellitus with the
cohort with nonischemic cardiomyopathy.
Survival in revascularized diabetics with ischemic cardio-
myopathy. The baseline characteristics of subjects with and
without a history of coronary artery bypass graft surgery
were compared in the diabetic and nondiabetic cohorts
(Tables 5 and 6). The subjects without surgical revascular-
ization were more likely to be female and African-American
in the diabetic and nondiabetic cohorts. Of the patients with
Figure 1. Survival free from all-cause mortality in the three cohorts in the Studies Of Left Ventricular Dysfunction (SOLVD) Prevention trial. The patients
with ischemic cardiomyopathy and diabetes (n 5 575; dashed line) had increased mortality compared with the patients with ischemic cardiomyopathy and
no diabetes (n 5 3,086; solid line) (p , 0.0001 by log-rank), but not significantly greater than that of the patients with nonischemic cardiomyopathy (n 5
562; dotted line) (p 5 0.21 by log-rank). The cohort with ischemic cardiomyopathy without diabetes (n 5 3,086; solid line) demonstrated significantly
lower mortality compared with the nonischemic cohort (p 5 0.007 by log-rank) and the ischemic cohort with diabetes.
Table 3. Prognostic Impact of Diabetes According to Etiology of Heart Failure: Adjusted
Analyses of the SOLVD Prevention and Treatment Trials Combined
Ischemic Etiology* Nonischemic Etiology†
RR (95% CI) p Value RR (95% CI) p Value
ACM 1.37 (1.21–1.55) ,0.0001 0.98 (0.76–1.32) 0.99
Pump failure 1.44 (1.18–1.76) 0.0003 0.91 (0.70–1.50) 0.91
Arrhythmia 1.25 (0.97–1.61) 0.09 0.99 (0.53–1.87) 0.99
MI 1.21 (0.85–1.72) 0.29 1.09 (0.38–3.13) 0.86
ACM or hospital admission for CHF 1.51 (1.36–1.68) ,0.0001 1.17 (0.94–1.46) 0.16
*Adjusted for age, ejection fraction, New York Heart Association functional class, baseline creatinine value, gender, race (black
vs. non-black), baseline use of beta-blocker or aspirin, coronary artery bypass graft surgery (CABG) and randomization to
enalapril or placebo. †Adjusted for same covariates, except CABG.
ACM 5 all-cause mortality; CHF 5 congestive heart failure; CI 5 confidence interval; MI 5 myocardial infarction; RR 5
relative risk; SOLVD 5 Studies Of Left Ventricular Dysfunction.
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diabetes mellitus, those without surgical revascularization
did not differ from those with surgical revascularization with
regard to mean ejection fraction, severity of heart failure, as
assessed by NYHA functional class, measures of vascular
disease (pulse pressure and history of stroke) and baseline
renal function, as assessed by the creatinine value. The
unadjusted incidence of all-cause mortality (Table 7) in
these groups demonstrates that previous surgical revascular-
ization identifies a subgroup within the ischemic cardiomy-
opathy/diabetes mellitus cohort with improved survival, and
the absolute magnitude of the unadjusted mortality reduc-
tion associated with previous surgical revascularization is
greater in the patients with diabetes mellitus.
DISCUSSION
Major findings. The original SOLVD investigators iden-
tified diabetes as a strong independent predictor of mortality
in patients with heart failure (1). The present analysis
extends these findings and adds to our understanding of the
impact of diabetes in patients with heart failure. Several of
these findings deserve emphasis. First, the prognostic im-
pact of diabetes mellitus in systolic heart failure appears to
Figure 2. Survival free from all-cause mortality in the three cohorts in the Studies Of Left Ventricular Dysfunction (SOLVD) Treatment trial. The patients
with ischemic cardiomyopathy and diabetes (n 5 534; dashed line) had increased mortality compared with the patients with ischemic cardiomyopathy
without diabetes (n 5 1,392; solid line) and patients with nonischemic cardiomyopathy (n 5 642; dotted line) (p , 0.0001 log-rank for both comparisons.)
There was no significant difference in survival between the patients with ischemic cardiomyopathy without diabetes and the patients with nonischemic
cardiomyopathy.
Table 4. Adjusted Analyses of Cohort Survival
Cause of
Death
RR (95% CI) p Value





0.99 (0.86–1.15) 1.22 (0.99–1.50) 0.81 (0.61–1.08) 0.40 (0.25–0.66) 1.15 (1.02–1.29)
0.99 0.07 0.16 0.0003 0.022
Group 3 vs.
group 1†
1.37 (1.21–1.56) 1.45 (1.19–1.77) 1.25 (0.97–1.62) 1.20 (0.84–1.70) 1.51 (1.36–1.68)
,0.0001 0.0002 0.09 0.29 ,0.0001
Group 3 vs.
group 2*
1.45 (1.22–1.72) 1.29 (1.01–1.65) 1.54 (1.08–2.19) 3.16 (1.78–5.61) 1.37 (1.19–1.57)
,0.0001 0.04 0.02 ,0.0001 ,0.0001
*Adjusted for age, ejection fraction, New York Heart Association functional class, SOLVD trial (Treatment vs. Prevention trial), gender, race, baseline use of beta-blocker or
aspirin and randomization to enalapril or placebo. †Adjusted for the same variables as just listed, plus surgical revascularization. Group 1 (reference group): ischemic nondiabetic
cohort (n 5 4,478); Group 2: nonischemic cohort with and without diabetes (n 5 1,204); and Group 3: ischemic diabetic cohort (n 5 1,109).
SCD 5 sudden cardiac death; other abbreviations as in Table 3.
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be determined by the etiology of left ventricular systolic
dysfunction. Specifically, diabetes mellitus was strongly
associated with an increased risk of mortality in subjects
with ischemic cardiomyopathy, but there was no association
between diabetes mellitus and mortality risk in those with
nonischemic cardiomyopathy. Second, the prevailing opin-
ion is that ischemic cardiomyopathy is associated with an
adverse prognosis, compared with nonischemic cardiomy-
opathy (5). Our data suggest that the adverse prognosis
associated with ischemic cardiomyopathy is limited to pa-
tients with diabetes mellitus. In fact, once these patients are
excluded, the adjusted mortality risk is essentially identical
in patients with ischemic and nonischemic cardiomyopathy.
Third, it appears that previous surgical revascularization is
associated with a reduction in the adverse prognostic impact
of diabetes in patients with ischemic cardiomyopathy and
diabetes mellitus.
Impact of diabetes on modes of death in ischemic
cardiomyopathy. An interesting finding was the spectrum
of risk associated with the various modes of death in the
patients with ischemic cardiomyopathy stratified according
to diabetes mellitus. Diabetes mellitus is associated with
Table 5. Baseline Characteristics of Patients Stratified by Coronary Artery Bypass Graft Surgery
and Diabetes Status: SOLVD Prevention Trial









Age (years) 61.9 6 8.2 61.4 6 9.2 60.3 6 9.1 58.5 6 10.6*
Ejection fraction (%) 28.8 6 4.8 28.6 6 5.8 28.9 6 5.3 28.3 6 5.6†
Creatinine (mg/dl) 1.15 6 0.24 1.16 6 0.31 1.17 6 0.26 1.14 6 0.25‡
History of CVA 9.0% 7.2% 6.2% 5.3%
History of hypertension 46.3% 54.0% 36.6% 32.3%‡
Atrial fibrillation 2.5% 3.2% 2.5% 2.2%
Pulse pressure (mm Hg) 40.2 6 6.8 39.2 6 7.4 37.2 6 6.9 36.8 6 6.9
Gender
Male 91% 85%‡ 95% 88%*
Female 9% 15%‡ 5% 12%*
Race
Black 7% 17%* 4% 7%*
White 93% 83%* 96% 93%*
NYHA functional class
II 35% 37% 32% 33%
I 65% 63% 68% 67%
*p # 0.001; †p # 0.01 and .0.001; ‡p # 0.05 and .0.01. Data are presented as the mean value 6 SD or percentage of patients.
CVA 5 cerebrovascular accident; NYHA 5 New York Heart Association; other abbreviations as in Table 1.
Table 6. Baseline Characteristics of Patients Stratified by Coronary Artery Bypass Graft Surgery
and Diabetes Status: SOLVD Treatment Trial









Age (years) 62.8 6 8.0 63.3 6 8.0 61.4 6 9.0 61.5 6 9.4
Ejection fraction (%) 27.2 6 5.7 25.6 6 6.7† 25.7 6 6.4 24.7 6 6.7†
Creatinine (mg/dl) 1.29 6 0.38 1.24 6 0.33 1.25 6 0.29 1.23 6 0.30
History of CVA 8.2% 10.6% 9.7% 7.3%
History of hypertension 48.3% 53.5% 36.4% 37.6%
Atrial fibrillation 5.4% 6.7% 5.8% 5.9%
Pulse pressure (mm Hg) 39.8 6 8.5 39.5 6 7.9 38.1 6 8.2 37.5 6 7.7
Gender
Male 83% 76% 89% 82%*
Female 17% 24% 11% 18%*
Race
Black 11% 19%‡ 5% 10%†
White 89% 81%‡ 95% 90%†
NYHA functional class
IV 4% 2% 1% 1%
III 35% 38% 27% 28%
II 57% 54% 58% 58%
I 4% 6% 14% 13%
*p # 0.001; †p # 0.01 and .0.001; ‡p # 0.05 and .0.01. Data are presented as the mean value 6 SD or percentage of patients.
Abbreviations as in Tables 1 and 5.
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more diffuse and severe coronary artery disease and in-
creased mortality from acute coronary syndromes and myo-
cardial infarction (7–9). Therefore, the increased mortality
in the patients with ischemic cardiomyopathy and diabetes
mellitus might be expected. However, the increased risk of
all-cause mortality in the subjects with ischemic cardiomy-
opathy and a history of diabetes mellitus, compared with
those without a history of diabetes mellitus, was related to
an increased risk of progression of heart failure, as suggested
by the increased risk of pump failure death and the com-
posite end point of death from any cause or hospital
admission for heart failure. The risk of myocardial infarction
did not reach statistical significance. There was a trend
toward an increased risk of arrhythmic death in the patients
with ischemic cardiomyopathy and diabetes, compared with
those without diabetes mellitus. However, we know from a
recent autopsy study that recurrent myocardial infarction
accounts for many deaths in patients with ischemic cardio-
myopathy (10). The trend toward greater arrhythmic death
in the subjects with diabetes and ischemic cardiomyopathy,
compared with those without diabetes mellitus, may sug-
gest, based on published data (10), that many of the deaths
attributed to a fatal arrhythmia may indeed have resulted
from a myocardial infarction. Finally, nonfatal infarctions
may have been more common in the subjects with diabetes
mellitus and ischemic cardiomyopathy and resulted in ac-
celeration of left ventricular dysfunction.
Impact of surgical revascularization. Previous surgical
revascularization identified a subgroup within the diabetic
cohort with ischemic cardiomyopathy with substantially
lower mortality. The adverse prognosis in the nonrevascu-
larized diabetic patients with systolic dysfunction may re-
flect the influence of selection bias in the determination of
which diabetics with ischemic cardiomyopathy were offered
surgical revascularization. Interestingly, the baseline charac-
teristics of the diabetics with and without surgical revascu-
larization did not identify obvious differences in comorbidi-
ties or measures of the severity of heart failure between the
groups that might be expected to detract from their candi-
dacy for surgical revascularization. However, it should be
emphasized that surgical revascularization was not a ran-
domized treatment, and we had little data on the complete-
ness of revascularization in each subject. These patients
were highly selected in an era when surgical revasculariza-
tion was often not performed on the basis of a low ejection
fraction, and the presence of diabetes may have created a
selection bias explaining these results.
Potential explanations for the interaction between dia-
betes and etiology of heart failure. The differential impact
of diabetes on mortality according to the etiology of heart
failure suggests that diabetes mellitus and ischemic heart
disease interact to accelerate the progression of myocardial
dysfunction. As mentioned already, this may be partly
explained by an increased risk of nonfatal myocardial infarc-
tions, incomplete revascularization in those who had surgi-
cal revascularization or comorbidities resulting from diabe-
tes. However, as hypothesis-generating, these data suggest
that there may be additional mechanisms for a deleterious
synergy between these two disease processes. For example,
ischemic cardiomyopathy is characterized by a shift in
myocardial substrate utilization from free fatty acids to
increased reliance on glucose and glycolysis (2,3,11,12).
This has been demonstrated in animal models mimicking
the chronic decrease in coronary blood flow that is thought
to characterize hibernating myocardium (2,3). Glucose up-
take into cardiomyocytes requires insulin (4) and has been
demonstrated to be impaired in an animal model of type II
diabetes (13). In the presence of the greater reliance on
glycolysis and decreased reliance of free fatty acid metabo-
lism that occurs in chronic coronary artery disease, the
impaired myocardial glucose uptake characteristic of diabe-
tes may be particularly deleterious (2,3). In addition, the
cumulative oxidative stress of chronic ischemia may be
additive to the oxidative stress superimposed by diabetes.
This oxidative stress results in myocardial subcellular re-
modeling, leading to abnormal intracellular calcium ho-
meostasis (14).
Study limitations. The limitations of this retrospective
study must be emphasized. The determination of the exact
etiology of heart failure was not based on routine cardiac
catheterization, and it is likely that there was some misclas-
sification. Surgical revascularization was not randomized,
but was determined by history at the time of randomization,
and we did not have data on the severity of coronary disease
or other factors that may have excluded some of the
Table 7. Incidence of Death and Modes of Death According to




CABG No CABG CABG No CABG
ACM 4.1% 4.9% 5.4% 9.3%*
Pump failure 1.5% 1.2% 2.2% 2.6%
Arrhythmia 0.9% 1.9%* 1.1% 2.7%‡




6.1% 7.0% 9.4% 13.4%‡
Treatment Trial
No Diabetes Diabetes
CABG No CABG CABG No CABG
ACM 10.9% 13.9%‡ 12.5% 19.5%†
Pump failure 5.2% 6.1% 5.7% 9.9%‡
Arrhythmia 2.4% 3.7%‡ 2.6% 4.4%




16.0% 18.3% 19.5% 26.6%†
*p # 0.05 and p . 0.01 by log-rank; †Log-rank p # 0.01 and p . 0.001 by log-rank;
‡p # 0.001 by log-rank. Data are presented as the percentage of patients.
Abbreviations as in Table 3.
427JACC Vol. 38, No. 2, 2001 Dries et al.
August 2001:421–8 Prognostic Impact of Diabetes in Heart Failure
ischemic diabetic patients from receiving surgical revascu-
larization. Classification of the causes of death in heart
failure is imprecise and subject to misclassification. There-
fore, the data relating each cohort’s relative risk according to
the mode of death should be interpreted with caution.
Conclusions. The differential impact of diabetes on mor-
tality and heart failure progression, based on the etiology of
heart failure, suggests that diabetes and ischemic heart
disease interact to accelerate the progression of myocardial
dysfunction. Evaluation of the potential for revasculariza-
tion may be particularly important in patients with coronary
artery disease who have both diabetes and heart failure.
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